Ensuring integrity in industry-sponsored research: primum non nocere, revisited

JAMA. 2010 Mar 24;303(12):1196-8. doi: 10.1001/jama.2010.337.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Clinical Trials Data Monitoring Committees / ethics
  • Data Collection / ethics
  • Data Collection / standards
  • Data Interpretation, Statistical
  • Diabetes Mellitus, Type 2 / drug therapy
  • Drug Industry*
  • Editorial Policies
  • Endpoint Determination
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Meta-Analysis as Topic
  • Peer Review, Research / ethics*
  • Physician's Role*
  • Randomized Controlled Trials as Topic / ethics*
  • Rosiglitazone
  • Thiazolidinediones / adverse effects
  • Thiazolidinediones / therapeutic use

Substances

  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone